Latest News and Press Releases
Want to stay updated on the latest news?
-
Focused execution in Q2 2025 to advance Oculis’ pipeline in ophthalmology and neuro-ophthalmologyOCS-01: Both pivotal Ph3 DIAMOND trials are fully enrolled, with topline results expected in Q2 2026...
-
ZUG, Sviss, Aug. 21, 2025 (GLOBE NEWSWIRE) --Á öðrum ársfjórðungi 2025 vann Oculis markvisst að áframhaldandi þróun lyfja á sviði augn- og augntaugasjúkdóma.OCS-01: Innritun sjúklinga í báðar DIAMOND...
-
ZUG, Switzerland, Aug. 21, 2025 (GLOBE NEWSWIRE) --Focused execution in Q2 2025 to advance Oculis’ pipeline in ophthalmology and neuro-ophthalmology.OCS-01: Both pivotal Ph3 DIAMOND trials are fully...
-
ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and...
-
ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and...
-
ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...
-
ZUG, Sviss, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) („Oculis“ eða „félagið“), alþjóðlegt líftæknifyrirtæki með áherslu á nýsköpun við meðferð á augn- og...
-
ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...
-
ZUG, Switzerland, July 09, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to directors of the Company. Attachment ...
-
ZUG, Switzerland, June 09, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the annual equity incentive awards granted to directors of the Company. Attachments ...